Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02201992
Title Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.